Greenphire, expected to hit the block in April, ought to command dual interest from growth-oriented financial sponsors and a wide pool of strategic buyers, sources told PE Hub. Although a process has not formally launched, the firm hopes to fetch some $1 billion in a potential transaction, they said. Sources placed recurring revenue at $100 million, which would imply a roughly 10x multiple is desired.
Read the full article: Greenphire, a Riverside-backed Clinical Trial Payments Company, Preps for Sale //
Source: https://www.pehub.com/greenphire-riverside-backed-clinical-trial-payments-co-preps-for-sale